Immunotherapy in Squamous Cell Cancer of the Esophagus.
Treatment of esophageal carcinoma has changed dramatically following several landmark trials, which have proven the benefit of immunotherapy. The selective PD-1 (programmed cell death ligand-1)-inhibitor nivolumab has been shown to improve DFS in the adjuvant therapy setting (CheckMate-577). In the...
| Publicado en: | Current Oncology Vol. 29; no. 4; pp. 2461 - 2472 |
|---|---|
| Autores principales: | , |
| Formato: | Journal Article |
| Publicado: |
MDPI
Apr2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=156533350&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 156533350 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: Apr2022 vid: 29 iid: 4 pid: 97109 pub: MDPI artinfo: ui: 156533350 10.3390/curroncol29040200 156533350 ppf: 2461 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Immunotherapy in Squamous Cell Cancer of the Esophagus. aug: au: Thuss-Patience, Peter Stein, Alexander affil: Department of Hematology, Oncology and Cancer Immunology, Charité—University Medicine Berlin, 13353 Berlin, Germany sug: ab: Treatment of esophageal carcinoma has changed dramatically following several landmark trials, which have proven the benefit of immunotherapy. The selective PD-1 (programmed cell death ligand-1)-inhibitor nivolumab has been shown to improve DFS in the adjuvant therapy setting (CheckMate-577). In the first-line treatment, PD-L1 positive (CPS ≥ 10) squamous cell carcinoma patients (pts) have been shown to have an increased OS following treatment with the PD-1-inhibitor pembrolizumab in combination with chemotherapy (KEYNOTE-590). Nivolumab also improved overall survival in the first line setting either combined with ipilimumab or with chemotherapy (CheckMate 648) compared to chemotherapy alone. In Asian first-line patients, phase III trials investigating camrelizumab (ESCORT 1), toripalimab (JUPITER 06), or sintilimab (ORIENT 15) in addition to chemotherapy also showed significant survival benefits. In the second-line setting, monotherapy with nivolumab (ATTRACTION-03), pembrolizumab (KEYNOTE-181), camrelizumab (ESCORT), and tislelizumab (RATIONALE 302) demonstrated a benefit in OS in comparison to chemotherapy. Here we will review these trials and integrate them into the current treatment algorithm. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|